Biochemical and pharmacological characterization of FR134043, a novel elastase inhibitor

被引:13
|
作者
Shinguh, Y [1 ]
Yamazaki, A [1 ]
Inamura, N [1 ]
Fujie, K [1 ]
Okamoto, M [1 ]
Nakahara, K [1 ]
Notsu, Y [1 ]
Okuhara, M [1 ]
Ono, T [1 ]
机构
[1] Fujisawa Pharmaceut Co Ltd, Exploratory Res Labs, Tsukuba, Ibaraki 30026, Japan
关键词
FR134043; elastase inhibitor; elastase; adult respiratory distress syndrome; disseminated intravascular coagulation; septic shock; pulmonary emphysema; hemorrhage; edema;
D O I
10.1016/S0014-2999(98)00028-4
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
FR 134043, disodium(Z1S,15S,18S,24S,27R,29S,34S,37R)-29-benzyl-21-ethylidene-27-hydroxy-15-isobutyrylamino-34-isopropyl-31,37-dimethyl-10,16,19,22,30,32,35,38-octaoxo-36-oxa-9,11,17,20,23,28,31,33-octaazatetracyclo[16.13.61(24, 28).0(3, 8)]octatriconta-3,5,7-trien-5,6-diyl disulfate, is a water-soluble inhibitor of human neutrophil elastase with a molecular mass of 1166.15 Da. FR134043 demonstrated a characteristic competitive inhibition of human neutrophil elastase with a K-i of 8 nM. In studies using synthetic substrates, FR134043 inhibited both neutrophil elastase activity and porcine pancreatic elastase activity with IC50 values of 35 nM and 49 nM respectively. FR134043 also inhibited hydrolysis of bovine neck ligament elastin by human neutrophil elastase with an IC50 value of 210 nM. In in vivo experiments, FR134043 protected animals against human neutrophil elastase (50 mu g/animal)-induced lung hemorrhage in hamsters with an ED50 value of 3.1 mu g/animal for intratracheal administration and 5.0 mg/kg for intravenous administration. Subcutaneous treatment with FR134043 significantly suppressed human neutrophil elastase (20 mu g/paw)-induced paw edema in mice with an ED50 value of 3.3 mg/kg when evaluated 4 h after elastase injection. The potency of FR134043 given intratracheally to protect against porcine pancreatic elastase (100 mu g/animal)-induced emphysema in hamsters was relatively low (Quasi-static lung compliance; ED50 = 1590 mu g/animal) compared to that in acute animal models. FR134043 (10 mg/kg per h i.v. infusion) significantly improved lipopolysaccharide (0.25 mg/kg per h i.v. infusion)-induced thrombocytopenia and some coagulation parameters in rats. These results suggest that systemic administration of FR134043 would be advantageous over intratracheal administration of FR134043 for the treatment of adult respiratory distress syndrome, septic shock and pulmonary emphysema and other pathophysiologic conditions in which elastases are thought to be involved. (C) 1998 Elsevier Science B.V.
引用
收藏
页码:299 / 308
页数:10
相关论文
共 50 条
  • [31] Pharmacological profile of FR260330, a novel orally active inducible nitric oxide synthase inhibitor
    Chida, N
    Hirasawa, Y
    Ohkawa, T
    Ishii, Y
    Sudo, Y
    Tamura, K
    Mutoh, S
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2005, 509 (01) : 71 - 76
  • [32] BIOCHEMICAL AND PHARMACOLOGICAL ASPECTS OF THE THROMBIN INHIBITOR HIRUDIN
    WALSMANN, P
    MARKWARDT, F
    PHARMAZIE, 1981, 36 (10): : 653 - 660
  • [33] Pharmacological characterization of a novel factor Xa inhibitor, FXV673
    Chu, V
    Brown, K
    Colussi, D
    Gao, JB
    Bostwick, J
    Kasiewski, C
    Bentley, R
    Morgan, S
    Guertin, K
    Pauls, HW
    Gong, Y
    Zulli, A
    Perrone, MH
    Dunwiddie, CT
    Leadley, RJ
    THROMBOSIS RESEARCH, 2001, 103 (04) : 309 - 324
  • [34] Pharmacological evaluation of FK706, a novel and potent elastase inhibitor (vol 73, pg 114, 1997)
    Yamazaki, A
    Shinguh, Y
    Inamura, N
    Nakahara, K
    Shimomura, K
    Ono, T
    JAPANESE JOURNAL OF PHARMACOLOGY, 1997, 74 (04): : 341 - 341
  • [35] Biochemical and pharmacological characterization of the novel NO-donor, SP/W-5186
    Knuttel, K
    Meese, CO
    Bokens, H
    Spahr, R
    Friehe, H
    Rees, D
    Follenfant, MJ
    Whittle, BJR
    Feelisch, M
    BIOLOGY OF NITRIC OXIDE, PT 5, 1996, 10 : 189 - 189
  • [36] Biochemical and cellular characterization of the novel proteasome inhibitor PR-171.
    Demo, SD
    Buchholz, TJ
    Laidig, GJ
    Parlati, F
    Shenk, KD
    Smyth, MS
    Sullivan, CM
    Sun, CM
    Vallone, MK
    Woo, T
    Bennett, MK
    BLOOD, 2005, 106 (11) : 455A - 455A
  • [37] BIOCHEMICAL DEFINITION OF THE SYNERGISM BETWEEN PSEUDOMONAS ELASTASE, ALPHA-1-PROTEASE INHIBITOR AND NEUTROPHIL ELASTASE
    FICK, RB
    SQUIER, SU
    CLINICAL RESEARCH, 1986, 34 (02): : A577 - A577
  • [38] Biochemical characterization of a novel carboxypeptidase inhibitor from a variety of Andean potatoes
    Lufrano, Daniela
    Cotabarren, Juliana
    Garcia-Pardo, Javier
    Fernandez-Alvarez, Roberto
    Tort, Olivia
    Tanco, Sebastian
    Xavier Aviles, Francesc
    Lorenzo, Julia
    Obregon, Walter D.
    PHYTOCHEMISTRY, 2015, 120 : 36 - 45
  • [39] Structure of the complex of porcine pancreatic elastase with a trimacrocyclic peptide inhibitor FR901451
    Kinoshita, T
    Kitatani, T
    Warizaya, M
    Tada, T
    ACTA CRYSTALLOGRAPHICA SECTION F-STRUCTURAL BIOLOGY COMMUNICATIONS, 2005, 61 : 808 - 811
  • [40] Pharmacological Characterization of SAR407899, a Novel Rho-Kinase Inhibitor
    Loehn, Matthias
    Plettenburg, Oliver
    Ivashchenko, Yuri
    Kannt, Aimo
    Hofmeister, Armin
    Kadereit, Dieter
    Schaefer, Matthias
    Linz, Wolfgang
    Kohlmann, Markus
    Herbert, Jean-Marc
    Janiak, Philip
    O'Connor, Stephen E.
    Ruetten, Hartmut
    HYPERTENSION, 2009, 54 (03) : 676 - 683